Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025506 · OUTCOME

Initial Performance Status

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
baseline

What was measured

Performance status 0 = Fully active, able to carry on all pre-disease performance without restriction. Performance status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work. Performance status 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.

Analysis population: Eligible and evaluable patients

Groups in this outcome

Thalidomide

Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Thalidomide45

Reported measurements

Source class 1

Performance status = 0

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Thalidomide30Not reportedNot reportedNot reportedNot reported

Performance status = 1

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Thalidomide12Not reportedNot reportedNot reportedNot reported

Performance status = 2

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Thalidomide3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        30
      title
      Performance status = 0
    2. measurements
      1. group Id
        OG000
        value
        12
      title
      Performance status = 1
    3. measurements
      1. group Id
        OG000
        value
        3
      title
      Performance status = 2
denoms
  1. counts
    1. group Id
      OG000
      value
      45
    units
    Participants
description
Performance status 0 = Fully active, able to carry on all pre-disease performance without restriction. Performance status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work. Performance status 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
groups
  1. description
    Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.
    id
    OG000
    title
    Thalidomide
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible and evaluable patients
reporting Status
POSTED
time Frame
baseline
title
Initial Performance Status
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice